- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01944462
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center (PPVP)
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center for Adults Aged 65 Years or Older or Those With Defined Risk Factors for Invasive Pneumococcal Disease
The overall goals of this program are to measure the impact of a pharmacist pneumococcal vaccine education program (PPVP) using a senior center model of care and provide the pneumococcal vaccine to eligible participants.
Hypotheses
- PPVP will result in improved knowledge and awareness in older minorities in the senior center setting (primary hypothesis);
- Participants who are vaccinated through the project will experienced increased trust in receiving vaccines from a pharmacist;
- Participants will be satisfied with and trust the PV information provided by pharmacists in the PPVP;
- PPVP is an efficient approach to educating patients in the senior center based on its costs;
- Participating pharmacists will be activated to implement PPVP learnings in their practice.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19144
- Center in the Park
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A. Inclusions for PPVP:
- Age ≥ 50 years old
- Can attend a 1.5-hour session at CIP
- Cognitively intact based on responses to an Abbreviated Mental Test Score (AMTS) of ≥7 (see Appendix for AMTS instrument)
- Can speak and read English at ≥4th grade level as evidenced by ability to read a brief passage
- Access to a telephone
B. Inclusions to receive the optional pneumococcal vaccination:
Patient meets ≥1 of the following criteria for receiving their first pneumococcal vaccination:
- All adults age 65 years and older who have not had the vaccine previously
Age 50-64 years with any of the following conditions:
- Cigarette smokers age 19 years and older
- Chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathies; excluding hypertension)
- Chronic pulmonary disease (including COPD and emphysema, and for adults ages 19 years and older, asthma)
- Diabetes mellitus
- Alcoholism
- Chronic liver disease, cirrhosis
- Candidate for or recipient of cochlear implant
- Functional or anatomic asplenia (e.g., sickle cell disease, splenectomy)
- Immunocompromising conditions or on immunosuppressive therapy
- Chronic renal failure or nephrotic syndrome
OR
Patient meets ≥1 of the following criteria for receiving a booster dose of the pneumococcal vaccination:
- Adults age 65 years and older who received their first dose for any indication when they were younger than age 65 years.
Adults age 50-64 who have not received the vaccine for ≥5 years and have one of the following conditions:
- Functional or anatomic asplenia (including persons with sickle cell disease or splenectomy patients);
- Chronic renal failure (including dialysis patients) or nephrotic syndrome;
- Immunocompromising conditions or on immunosuppressive therapy
Exclusion Criteria:
A. Exclusions to the PPVP program: none
B. Exclusions to receiving the optional pneumococcal vaccine:
- Participant has a history of allergic reaction to pneumococcal vaccine
- Participant has a history of allergic reaction to any component of any vaccine
- Participant with moderate or severe illness (these individuals will be advised to speak to their doctor regarding the vaccine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacist Pneumococcal Vaccine Program (PPVP)
Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
|
1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine.
Vaccination to be provided free of charge to eligible participants who opt to receive it.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knowledge and Awareness of Pneumococcal Disease
Time Frame: Baseline, post-test, 3 months
|
Change in knowledge and awareness of pneumococcal disease over time were assessed for the following domains: susceptibility to infection, symptoms of disease, severity of illness, and vaccination with an emphasis on vaccine efficacy, safety, and eligibility.
Assessments at baseline, post-test (immediately following intervention), and 3 months using the Pneumonia Knowledge Questionnaire, an instrument developed by investigators to assess participants' knowledge and awareness in the domains of interest.
Instrument consists of 5 "mark all that apply" items and one "mark the best response" item.
Scores range from 0 (no correct responses) to 28 (all responses correct), with a higher score value corresponding to better knowledge and awareness.
|
Baseline, post-test, 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Trust in Pharmacists as Vaccine Providers
Time Frame: Baseline, post-test (immediately following intervention), 3 months
|
Trust in pharmacists as vaccine providers were measured by comparing responses to the trust items in the baseline, post-test (immediately following intervention), and 3-month assessments.
Trust items were coded on a 4-level Likert scale, with lower values corresponding to higher agreement with the trust statements (therefore a lower mean response indicates greater trust).
Minimum possible score was 1 (indicating complete trust in pharmacists as vaccine providers) and maximum possible score was 4 (indicating complete lack of trust in pharmacists as vaccine providers).
|
Baseline, post-test (immediately following intervention), 3 months
|
Activation
Time Frame: 3 months
|
Activation was measured as number of participants having taken action at 3 months or planning action at baseline, post-test, and 3 months.
|
3 months
|
Satisfaction With PPPP
Time Frame: 3 months
|
Satisfaction with PPPP was measured as participants' overall satisfaction with the content of PPPP, extent to which the participant felt engaged, and belief that the program helped them learn about pneumonia and the vaccination.
|
3 months
|
Intervention Cost
Time Frame: 3 months
|
Measures PPPP intervention costs per participant.
Consists of total program costs divided by number of participants.
Value reported is the per-participant cost with measure type "number".
|
3 months
|
Pharmacist Satisfaction
Time Frame: 3 months
|
Pharmacists who participated in the intervention were surveyed to determine their satisfaction with the program, including: 1) satisfaction with live action skit, 2) belief that PPPP was successful in educating participants, 3) belief that PPPP was successful in building trust in pharmacists among participants, 4) belief that PPPP was successful in increasing acceptance of pharmacists as immunizers, and 5) belief that PPPP will decrease barriers to vaccination among participants.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Pizzi, PharmD, MPH, Thomas Jefferson University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Merck IISP ID 50926
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Study is Open to Seniors Age 50 or Older
-
Inonu UniversityRecruitingBeing in the 18-50 Age Population | Being Diagnosed With Frozen Shoulder by a Specialist Physician | Volunteer to Participate in the StudyTurkey
-
Mid Michigan Health CentersCompletedNo Conditions for This Study. All Male Patients 18 Years of Age or Older Were Administered the LUTS, MSHQ, and Patient Demographics QuestionnaireUnited States
-
Yonsei UniversityCompletedAdult Patients 20 Years of Age or Older Who Are Planning to Undergo Surgery Under General AnesthesiaKorea, Republic of
-
TC Erciyes UniversityCompletedThe Focus of Study is to Determine the Waist Circumference Values to Predict Overweight or Obesity
-
Lotus PharmaceuticalUnknownThe Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg | Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in | Subjects With Type 2 Diabetes Mellitus.Taiwan
-
Yonsei UniversityNot yet recruitingAdult Patients 20 Years of Age or Older Who Are Planning to Undergo Surgery Under General AnesthesiaKorea, Republic of
-
South Valley UniversityActive, not recruitingWe Conducted This Prospective Randomized Comparative Study to Compare Between Outcome of Laparoscopic and Open Orchiopexy of High InguinaEgypt
-
University Of PerugiaUnknownThe Primary Study Objective is to Assess the Efficacy and | Safety of Extended 4-week Heparin Prophylaxis Compared to | Prophylaxis Given for 8±2 Days After Planned Laparoscopic | Surgery for Colorectal Cancer. | The Clinical Benefit Will be Evaluated as the Difference in | the Incidence of... and other conditionsItaly
-
AO Clinical Investigation and Publishing DocumentationWithdrawnFracture of the Radial Head Which is Not Amendable to an Adequate Osteosynthesis | Post-traumatic Deformity or Arthroses | Failed Open Reduction Internal Fixation (ORIF) of a Radial Head Fracture | Failed Conservative Radial Head Fracture Treatment
-
Wuhan UniversityPeking University; PfizerUnknownThe Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores. | The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales. | Safety Evaluations Include: Laboratory Test Abnormalities; BARS... and other conditions
Clinical Trials on Pharmacist Pneumococcal Vaccine Program (PPVP)
-
GlaxoSmithKlineCompletedInfections, StreptococcalCzechia
-
Seema BhatRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
SanofiCompletedPneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal PneumoniaSwitzerland
-
University of UtahNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedRespiratory Tract Infections | Respiratory Tract Diseases | PneumoniaChina
-
SanofiCompletedPneumoccocal ImmunisationUnited States
-
French National Agency for Research on AIDS and...Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal PneumoniaSwitzerland
-
Centers for Disease Control and PreventionSouthcentral Foundation; Alaska Native Tribal Health ConsortiumCompletedPneumococcal InfectionsUnited States
-
University of MinnesotaCompletedChronic Kidney DiseaseUnited States